A61K 9/167
With an outer layer or coating comprising drug
Official title: {with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface (with further drug-free outer coating A61K9/5073)}
A61K9/167 (With an outer layer or coating comprising drug) appears on 1,146 US grants and 1,912 published applications in this corpus.
Search patents in A61K- Granted patents
- 1,146
- Published applications
- 1,912
- Assignees
- 811
- Inventors
- 2,905
- Latest grant
- 8 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 1 | 0 |
| 1978 | 0 | 0 |
| 1979 | 2 | 0 |
| 1980 | 0 | 0 |
| 1981 | 1 | 0 |
| 1982 | 2 | 0 |
| 1983 | 1 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 2 | 0 |
| 1989 | 3 | 0 |
| 1990 | 8 | 0 |
| 1991 | 7 | 0 |
| 1992 | 9 | 0 |
| 1993 | 8 | 0 |
| 1994 | 7 | 0 |
| 1995 | 9 | 0 |
| 1996 | 15 | 0 |
| 1997 | 13 | 0 |
| 1998 | 15 | 0 |
| 1999 | 24 | 0 |
| 2000 | 25 | 0 |
| 2001 | 29 | 5 |
| 2002 | 29 | 38 |
| 2003 | 23 | 57 |
| 2004 | 14 | 67 |
| 2005 | 13 | 80 |
| 2006 | 18 | 62 |
| 2007 | 9 | 61 |
| 2008 | 19 | 71 |
| 2009 | 14 | 75 |
| 2010 | 32 | 84 |
| 2011 | 24 | 81 |
| 2012 | 34 | 69 |
| 2013 | 46 | 84 |
| 2014 | 66 | 100 |
| 2015 | 55 | 120 |
| 2016 | 77 | 113 |
| 2017 | 57 | 81 |
| 2018 | 53 | 80 |
| 2019 | 55 | 88 |
| 2020 | 64 | 90 |
| 2021 | 58 | 97 |
| 2022 | 46 | 84 |
| 2023 | 41 | 67 |
| 2024 | 54 | 72 |
| 2025 | 41 | 54 |
| 2026 | 21 | 32 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics8 Sep 2026US 12,728,110 B2Flamel Ireland Limited
- Liquisolid pharmaceutical formulation and process for manufacturing8 Sep 2026US 12,728,134 B2Rheinische Friedrich-Wilhelms-Universität Bonn
- JAK inhibitors having a specific particle size distribution25 Aug 2026US 12,714,674 B2Elanco US Inc.
- Multivalent nanoparticle-based vaccines23 Jun 2026US 12,661,322 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Coated granules produced by in-situ crosslinking process16 Jun 2026US 12,653,221 B2Danisco US Inc.
- Particle-based multi-layer therapeutic delivery device and method3 Sep 2026US 2026/0256710 A1Privo Technologies, Inc.
- Phospholipid compounds and formulations27 Aug 2026US 2026/0248830 A1AVVIO Medical, Inc.
- Solid oral dosage form comprising antibodies for sustained release in the lower gastrointestinal tract20 Aug 2026US 2026/0240774 A1Tillotts Pharma AG
- Dexamethasone prodrug compositions and uses thereof20 Aug 2026US 2026/0240776 A1Ripple Therapeutics Corporation
- Glutathione-coated gold nanoparticles functionalized with lithium (lig-aunps) and uses thereof for the modulation of glycogen synthase kinase - 3 activity13 Aug 2026US 2026/0232592 A1Fondazione Policlinico Universitario Agostino Geme
Most cited
By later US patents
- Anti-angiogenic compositions and methods of use968US 5,716,981 AAngiogenesis Technologies, Inc. · 1998
- Solid carriers for improved delivery of active ingredients in pharmaceutical compositions930US 6,248,363 B1Lipocine Inc. · 2001
- Method for producing microparticles loaded with proteins791US 7,335,401 B2Roche Diagnostic Operations, Inc. · 2008
- Solid carriers for improved delivery of active ingredients in pharmaceutical compositions684US 6,923,988 B2Lipocine Inc. · 2005
- Solid carriers for improved delivery of hydrophobic active ingredients in pharmaceutical compositions616US 6,569,463 B2Lipocine Inc. · 2003